{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:48:29Z","timestamp":1791388109648,"version":"4.3.3"},"reference-count":52,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,12,1]],"date-time":"2010-12-01T00:00:00Z","timestamp":1291161600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2010,12]]},"DOI":"10.1016\/j.jneuroim.2010.08.023","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T05:01:57Z","timestamp":1286168517000},"page":"256-262","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":60,"title":["IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN"],"prefix":"10.1016","volume":"229","author":[{"given":"Sanne","family":"Piepers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc D.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth A.","family":"Cats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina M.","family":"van Sorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard H.","family":"van den Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.-Ludo","family":"van der Pol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2010.08.023_bb0005","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0022-510X(98)00283-4","article-title":"The pattern of antiganglioside antibody reactivities producing myelinated nerve conduction block in vitro","volume":"161","author":"Arasaki","year":"1998","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0010","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jnnp.62.4.391","article-title":"Long term follow up of multifocal motor neuropathy with conduction block under treatment","volume":"62","author":"Azulay","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0015","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1172\/JCI117520","article-title":"High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments","volume":"94","author":"Basta","year":"1994","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0020","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jnnp.59.1.38","article-title":"Multifocal motor neuropathy with conduction block: a study of 24 patients","volume":"59","author":"Bouche","year":"1995","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0025","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1002\/ana.10205","article-title":"Intravenous immunoglobulins neutralize blocking antibodies in Guillain\u2013Barre syndrome","volume":"51","author":"Buchwald","year":"2002","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0030","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1212\/WNL.50.5.1480","article-title":"Deterioration of multifocal motor neuropathy after plasma exchange","volume":"50","author":"Carpo","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0035","unstructured":"Cats, E.A., Jacobs, B.C., Yuki, N. Tio-Gillen, A.P., Piepers, S., Franssen, H., Van Asseldonk, J.Th., Van den Berg, L.H., Van der Pol, W.L., in press. Multifocal motor neuropathy: association of anti-GM1 IgM antibodies with clinical features, Neurology."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1136\/jnnp.68.4.533","article-title":"Plasmapheresis in multifocal motor neuropathy: a case report","volume":"68","author":"Claus","year":"2000","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0045","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1212\/WNL.43.4.809","article-title":"Localization of GM1 and Gal(beta 1-3)GalNAc antigenic determinants in peripheral nerve","volume":"43","author":"Corbo","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0050","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1136\/jnnp.57.7.778","article-title":"Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin","volume":"57","author":"Donaghy","year":"1994","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0055","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/ncpneuro0376","article-title":"Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues","volume":"3","author":"Gold","year":"2007","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0060","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1093\/brain\/awh231","article-title":"Anti-disialoside antibodies kill perisynaptic Schwann cells and damage motor nerve terminals via membrane attack complex in a murine model of neuropathy","volume":"127","author":"Halstead","year":"2004","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0065","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1529-8027.2008.00181.x","article-title":"C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome","volume":"13","author":"Halstead","year":"2008","journal-title":"J. Peripher. Nerv. Syst."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0070","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1093\/brain\/awm316","article-title":"Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model","volume":"131","author":"Halstead","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0075","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0960-8966(00)00191-7","article-title":"79(th) ENMC International Workshop: multifocal motor neuropathy. 14-15 April 2000, Hilversum, The Netherlands","volume":"11","author":"Hughes","year":"2001","journal-title":"Neuromuscul. Disord."},{"issue":"Suppl 3","key":"10.1016\/j.jneuroim.2010.08.023_bb0080","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s00415-008-3003-z","article-title":"The role of IVIg in autoimmune neuropathies: the latest evidence","volume":"255","author":"Hughes","year":"2008","journal-title":"J. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0085","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1093\/brain\/awg235","article-title":"Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding","volume":"126","author":"Jacobs","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0090","series-title":"Experimental immunochemistry","first-page":"133","article-title":"Complement and complement fixation","author":"Kabat","year":"1967"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jns.2005.07.009","article-title":"Diagnostic value of anti-GM1 ganglioside serology and validation of the INCAT-ELISA","volume":"239","author":"Kuijf","year":"2005","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0100","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/brain\/124.1.145","article-title":"Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study","volume":"124","author":"Leger","year":"2001","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/S0165-5728(02)00139-X","article-title":"High affinity as a disease determinant factor in anti-GM(1) antibodies: comparative characterization of experimentally induced vs. disease-associated antibodies","volume":"128","author":"Lopez","year":"2002","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0110","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2003-05-1530","article-title":"Intravenously applied IgG stimulates complement attenuation in a complement-dependent autoimmune disease at the amplifying C3 convertase level","volume":"103","author":"Lutz","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0115","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jneuroim.2006.08.010","article-title":"Long-term evolution of anti-ganglioside antibody levels in patient with chronic dysimmune neuropathy under IVIg therapy","volume":"181","author":"Mata","year":"2006","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/jnnp.63.6.765","article-title":"Long term effect of intravenous immunoglobulins and oral cyclophosphamide in multifocal motor neuropathy","volume":"63","author":"Meucci","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0125","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/jnnp.72.6.761","article-title":"Multifocal motor neuropathy: clinical and immunological features and response to IVIg in relation to the presence and degree of motor conduction block","volume":"72","author":"Nobile-Orazio","year":"2002","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0130","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/mus.20296","article-title":"Multifocal motor neuropathy: current concepts and controversies","volume":"31","author":"Nobile-Orazio","year":"2005","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0135","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1097\/00005072-199602000-00007","article-title":"Anti-GM1 ganglioside antibodies cloned from autoimmune neuropathy patients show diverse binding patterns in the rodent nervous system","volume":"55","author":"O'Hanlon","year":"1996","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0140","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1093\/brain\/124.5.893","article-title":"Anti-GQ1b ganglioside antibodies mediate complement-dependent destruction of the motor nerve terminal","volume":"124","author":"O'Hanlon","year":"2001","journal-title":"Brain"},{"issue":"Pt 5","key":"10.1016\/j.jneuroim.2010.08.023_bb0145","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/brain\/122.5.807","article-title":"Anti-ganglioside antibodies can bind peripheral nerve nodes of Ranvier and activate the complement cascade without inducing acute conduction block in vitro","volume":"122","author":"Paparounas","year":"1999","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0150","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1212\/WNL.51.6_Suppl_5.S22","article-title":"Multifocal motor neuropathy: diagnosis and treatment","volume":"51","author":"Pestronk","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0155","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1212\/WNL.49.5.1289","article-title":"Multifocal motor neuropathy. Serum IgM anti-GM1 ganglioside antibodies in most patients detected using covalent linkage of GM1 to ELISA plates","volume":"49","author":"Pestronk","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0160","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/ana.410240113","article-title":"A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside","volume":"24","author":"Pestronk","year":"1988","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0165","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jneuroim.2008.09.016","article-title":"Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain\u2013Barre syndrome","volume":"205","author":"Phongsisay","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0170","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ana.410380118","article-title":"Multifocal motor neuropathy human sera block distal motor nerve conduction in mice","volume":"38","author":"Roberts","year":"1995","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0175","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/ana.410310407","article-title":"Experimental conduction block induced by serum from a patient with anti-GM1 antibodies","volume":"31","author":"Santoro","year":"1992","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0180","doi-asserted-by":"crossref","first-page":"3956","DOI":"10.1523\/JNEUROSCI.4401-06.2007","article-title":"Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers","volume":"27","author":"Susuki","year":"2007","journal-title":"J. Neurosci."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0185","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1212\/WNL.47.4.951","article-title":"The sensitivity and specificity of anti-GM1 antibody testing","volume":"47","author":"Taylor","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0190","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1093\/glycob\/cwl074","article-title":"Solid phase immunoadsorption for therapeutic and analytical studies on neuropathy-associated anti-GM1 antibodies","volume":"17","author":"Townson","year":"2007","journal-title":"Glycobiology"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0195","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000007916","article-title":"Antiganglioside GM1 antibodies and their complement activating capacity in central and peripheral nervous system disorders and in controls","volume":"39","author":"Uetz-von","year":"1998","journal-title":"Eur. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0200","first-page":"CD003217","article-title":"Immunosuppressant and immunomodulatory treatments for multifocal motor neuropathy","author":"Umapathi","year":"2009","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0205","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/mus.880160606","article-title":"Conduction abnormalities induced by sera of patients with multifocal motor neuropathy and anti-GM1 antibodies","volume":"16","author":"Uncini","year":"1993","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1136\/jnnp.55.1.8","article-title":"Anti-GM1 antibodies in patients with Guillain\u2013Barre syndrome","volume":"55","author":"Van den Berg","year":"1992","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0215","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/WNL.48.4.1135","article-title":"Pulsed high-dose dexamethasone is not effective in patients with multifocal motor neuropathy","volume":"48","author":"Van den Berg","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0220","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/1531-8249(200012)48:6<919::AID-ANA13>3.0.CO;2-J","article-title":"Multifocal motor neuropathy: diagnostic criteria that predict the response to immunoglobulin treatment","volume":"48","author":"Van den Berg-Vos","year":"2000","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0225","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1212\/WNL.45.8.1570","article-title":"Diagnostic value of GM1 antibodies in motor neuron disorders and neuropathies: a meta-analysis","volume":"45","author":"Van Schaik","year":"1995","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0230","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/ana.10503","article-title":"Anti-GM1 IgG antibodies induce leukocyte effector functions via Fcgamma receptors","volume":"53","author":"Van Sorge","year":"2003","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0235","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1568-9972(03)00089-2","article-title":"Pathogenicity of anti-ganglioside antibodies in the Guillain\u2013Barre syndrome","volume":"3","author":"Van Sorge","year":"2004","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0240","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jneuroim.2006.10.005","article-title":"Leukocyte and complement activation by GM1-specific antibodies is associated with acute motor axonal neuropathy in rabbits","volume":"182","author":"Van Sorge","year":"2007","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0245","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1212\/01.WNL.0000140497.85952.FA","article-title":"Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg","volume":"63","author":"Vucic","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0250","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1093\/brain\/awf272","article-title":"Peripheral neuropathies and anti-glycolipid antibodies","volume":"125","author":"Willison","year":"2002","journal-title":"Brain"},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0255","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jneuroim.2008.05.028","article-title":"The role of complement and complement regulators in mediating motor nerve terminal injury in murine models of Guillain\u2013Barre syndrome","volume":"201\u2013202","author":"Willison","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.jneuroim.2010.08.023_bb0260","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/0022-510X(96)00053-6","article-title":"Possible mechanism of intravenous immunoglobulin treatment on anti-GM1 antibody-mediated neuropathies","volume":"139","author":"Yuki","year":"1996","journal-title":"J. Neurol. Sci."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572810004042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572810004042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:14:49Z","timestamp":1759047289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572810004042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12]]},"references-count":52,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["S0165572810004042"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2010.08.023","relation":{},"ISSN":["0165-5728"],"issn-type":[{"value":"0165-5728","type":"print"}],"subject":[],"published":{"date-parts":[[2010,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IVIg inhibits classical pathway activity and anti-GM1 IgM-mediated complement deposition in MMN","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2010.08.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}